Compare FN & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FN | GH |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 13.3B |
| IPO Year | 2010 | 2018 |
| Metric | FN | GH |
|---|---|---|
| Price | $495.69 | $104.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 21 |
| Target Price | ★ $489.14 | $102.81 |
| AVG Volume (30 Days) | 787.0K | ★ 2.0M |
| Earning Date | 02-02-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.68 | N/A |
| EPS | ★ 10.43 | N/A |
| Revenue | ★ $3,892,507,000.00 | $902,569,000.00 |
| Revenue This Year | $33.48 | $35.23 |
| Revenue Next Year | $17.13 | $27.38 |
| P/E Ratio | $47.51 | ★ N/A |
| Revenue Growth | 24.66 | ★ 30.38 |
| 52 Week Low | $148.55 | $34.88 |
| 52 Week High | $531.22 | $120.74 |
| Indicator | FN | GH |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 45.64 |
| Support Level | $458.07 | $100.26 |
| Resistance Level | $512.38 | $108.51 |
| Average True Range (ATR) | 33.97 | 5.98 |
| MACD | -1.64 | -1.09 |
| Stochastic Oscillator | 53.05 | 31.71 |
Fabrinet provides advance-level optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and sub-systems, industrial lasers, automotive components, medical devices, and sensors. The company offers a broad range of advance optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, complex printed circuit board assembly, advance-level of packaging, integration, final assembly, and testing. The company generates the majority of its revenue from North America and Asia-Pacific, with the rest from Europe.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.